These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 6261672

  • 21. Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoencephalopathy lesions.
    Itoyama Y, Webster HD, Sternberger NH, Richardson EP, Walker DL, Quarles RH, Padgett BL.
    Ann Neurol; 1982 Apr; 11(4):396-407. PubMed ID: 6179456
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients.
    Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW.
    Transpl Infect Dis; 2007 Sep; 9(3):237-40. PubMed ID: 17692072
    [Abstract] [Full Text] [Related]

  • 25. Chronic progressive varicella-zoster virus encephalitis in an AIDS patient.
    Gilden DH, Murray RS, Wellish M, Kleinschmidt-DeMasters BK, Vafai A.
    Neurology; 1988 Jul; 38(7):1150-3. PubMed ID: 2838767
    [Abstract] [Full Text] [Related]

  • 26. Identification of viral antigens recognized by ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis.
    Milikan JC, Kinchington PR, Baarsma GS, Kuijpers RW, Osterhaus AD, Verjans GM.
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3689-97. PubMed ID: 17652740
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Multifocal varicella-zoster virus vasculopathy without rash.
    Russman AN, Lederman RJ, Calabrese LH, Embi PJ, Forghani B, Gilden DH.
    Arch Neurol; 2003 Nov; 60(11):1607-9. PubMed ID: 14623735
    [Abstract] [Full Text] [Related]

  • 29. Immune evasion as a pathogenic mechanism of varicella zoster virus.
    Abendroth A, Arvin AM.
    Semin Immunol; 2001 Feb; 13(1):27-39. PubMed ID: 11289797
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Molecular and therapeutic aspects of varicella-zoster virus infection.
    Quinlivan M, Breuer J.
    Expert Rev Mol Med; 2005 Aug 10; 7(15):1-24. PubMed ID: 16098235
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E, Schnürer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W.
    Biol Blood Marrow Transplant; 2008 Dec 10; 14(12):1417-24. PubMed ID: 19041065
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Defensive Perimeter in the Central Nervous System: Predominance of Astrocytes and Astrogliosis during Recovery from Varicella-Zoster Virus Encephalitis.
    Carpenter JE, Clayton AC, Halling KC, Bonthius DJ, Buckingham EM, Jackson W, Dotzler SM, Card JP, Enquist LW, Grose C.
    J Virol; 2016 Jan 01; 90(1):379-91. PubMed ID: 26491149
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.